Literature DB >> 3081066

Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation.

T Hercend, T Takvorian, A Nowill, R Tantravahi, P Moingeon, K C Anderson, C Murray, C Bohuon, A Ythier, J Ritz.   

Abstract

To identify cells with potential antileukemia activity following bone marrow transplantation, we have monitored immunologic reconstitution in a patient with acute lymphocytic leukemia in second remission who received intensive chemotherapy and total body irradiation followed by infusion of allogeneic histocompatible marrow. Prior to transplantation, donor bone marrow cells were depleted of T lymphocytes by in vitro treatment with anti-T12 monoclonal antibody and rabbit complement. In the first 3 weeks following bone marrow transplantation, the predominant regenerating mononuclear cell population in peripheral blood exhibited a phenotype characteristic of natural killer (NK) cells. After 4 weeks, T lymphocytes became predominant, but NK cells persisted. Cultured peripheral blood lymphocytes obtained 12 weeks posttransplant were able to display significant cytotoxicity against leukemic blasts that had been cryopreserved at the time of relapse 5 months prior to bone marrow transplantation. To further characterize those cells with antileukemia activity, we used in vitro cloning techniques to identify four monoclonal populations, termed TC12, -48, -50, and -59, with strong antitumor activity. Cytogenetic analysis demonstrated that each clone was of donor origin. Phenotypic characterization showed that the four clones expressed NKH1A but did not express T3, T4, or T8 antigens. Three of the four clones expressed T11/E rosette antigen. Each clone exhibited strong cytotoxicity against genetically unrelated hematopoietic tumor cell lines such as K562, Molt-4, JM, and U937. In addition, we found that these patient clones were similar to cloned NK cells previously derived from normal individuals. Taken together, these results suggest that at least some clones with antileukemia activity following bone marrow transplantation are cells with NK-like function and phenotype. Functional analysis of these cytolytic cells in larger numbers of patients will be necessary to determine the clinical significance of this finding.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081066

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 2.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 3.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

5.  GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.

Authors:  Mark D Bunting; Antiopi Varelias; Fernando Souza-Fonseca-Guimaraes; Iona S Schuster; Katie E Lineburg; Rachel D Kuns; Peter Fleming; Kelly R Locke; Nicholas D Huntington; Bruce R Blazar; Steven W Lane; Siok-Keen Tey; Kelli P A MacDonald; Mark J Smyth; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Blood       Date:  2016-12-07       Impact factor: 22.113

6.  Adaptive NK cell reconstitution is associated with better clinical outcomes.

Authors:  Frank Cichocki; Emily Taras; Flavia Chiuppesi; John E Wagner; Bruce R Blazar; Claudio Brunstein; Xianghua Luo; Don J Diamond; Sarah Cooley; Daniel J Weisdorf; Jeffrey S Miller
Journal:  JCI Insight       Date:  2019-01-24

Review 7.  Immune reconstitution following bone marrow transplantation.

Authors:  U N Verma; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 8.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

9.  Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy.

Authors:  J E Talmadge; J D Jackson; C D Borgeson; G A Perry
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

10.  Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

Authors:  S Morecki; S Revel-Vilk; C Nabet; M Pick; A Ackerstein; A Nagler; E Naparstek; M Ben Shahar; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.